Related Experiment Video
Updated: Jan 15, 2026
Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
Published on: March 10, 2023
The multiplex crosstalk between non-coding RNAs, programmed cell death and related mechanisms: a dynamic duo in
Mehrdad Hashemi1,2, Niloufar Salimian1,3, Nafiseh Sharifi1,4
1Farhikhtegan Medical Convergent Sciences Research Center, Farhikhtegan Hospital, Faculty of Medicine, TMs. C., Islamic Azad University, Tehran, Iran.
None:
Hematological malignancies, including leukemia, lymphoma, and multiple myeloma (MM), are cancers originating in the hematopoietic system, characterized by diverse pathogenesis and clinical features. Non-coding RNAs (ncRNAs) such as microRNAs (miRNAs) and long non-coding RNAs, play critical roles in regulating gene expression and influencing cell fate. Accumulating evidence indicates that ncRNAs are key modulators of programmed cell death (PCD) pathways, affecting tumor development, progression, and drug resistance in these malignancies. PCD, a precisely programmed and regulated cell death process, is vital for maintaining tissue homeostasis and preventing the proliferation of dangerous cells. NcRNAs are implicated in the primary mechanisms underlying the development of drug resistance. The evasion of PCD is a hallmark of cancer, and ncRNAs can significantly impact these pathways, with dysregulation observed across leukemia, lymphoma, and myeloma, influencing PCD pathways and clinical outcomes. Understanding the ncRNA-PCD interplay is crucial for developing novel therapeutic strategies and improving patient outcomes. This review explores the functions, regulatory mechanisms, and potential applications of ncRNAs in modulating PCD in hematological malignancies, particularly leukemias, providing insights for future anti-tumor therapies.
Related Concept Videos
01:01Regulation of Hematopoietic Stem Cells
01:19Multipotency of Hematopoietic Stem Cells
01:30Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:31The Intrinsic Apoptotic Pathway
01:21Lineage Commitment